Medpace (MEDP) Outperforms Broader Market: What You Need to Know

Medpace (MEDP) closed at $624.20, up 1.94%, outperforming the S&P 500's 1.49% gain. The clinical development services provider has a Zacks Rank #3 (Hold) rating with projected EPS growth of 15.28% and revenue growth of 7.4% for the upcoming quarter. However, the stock trades at a Forward P/E of 34.91, significantly above the industry average of 17.31, and has a PEG ratio of 2.73 compared to the industry average of 1.48, suggesting premium valuation.